# US 2016/0237055 A1 · Novel substituted n, n-dimethylaminoalkyl ethers of isoflavanone oximes as h1-receptor antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0237055 A1
- Document ID: US20160237055A1
- Status: Published application
- Kind: A1
- Application number: 15/023,210
- Filed: 2013-09-30
- Published: 2016-08-18
- Earliest claimed: 2013-09-30
- Assignees: Polfarmex S.A.
- Applicants: Polfarmex S.A.
- Inventors: Piotr Kopczacki; Mieczyslaw Wosko; Jaroslaw Walczak; Krzysztof Walczynski
- Web page: https://patentgrep.com/patent/US20160237055A1

## CPC

- C07D 311/68: with nitrogen atoms directly attached in position 4
- A61K 31/22: of acyclic acids, e.g. pravastatin
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 407/04: directly linked by a ring-member-to-ring-member bond
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to compounds of formula (I), and salts thereof and the pharmaceutical composition containing them in treatment of various diseases, as allergic rhinitis where R1 and R2 are, independently, hydrogen, halogen, C1_3 alkyl or C1-3alkoxy; R3 is phenyl optionally substituted by R4 and R5 which are, independently hydrogen, halogen, C1-3 alkyl, C1-3-alkoxy, fluoro-, difluoro- and trifluoromethyl, nitrile group, N,N-diC1-3alkyl-amide, carboC1-3 alkoxy or C1-3alkylsulphone groups; R3 is pyridyl group containing nitrogen at various positions in the benzene ring, n is one of the integers 1 or 2.

## Claims

### Claim 1

A compound, including enantiomers, stereoisomers, cis-, trans-isomers and their racemic mixture and mixture of geometric isomers, or pharmaceutically acceptable salts or solvates of said compound, said compound having the general structure shown in formula (I)
wherein
R1 and R2 are, independently, hydrogen, halogen, C1-3alkyl or C1-3alkoxy;
R3 is phenyl optionally substituted by R4 and R5 which are, independently hydrogen, halogen, C1-3alkyl, C1-3alkoxy, fluoro-, difluoro- and trifluoromethyl, nitrile group, N,N-diC1-3alkylamide, carboC1-3alkoxy or C1-3alkylsulphone groups; R3 is pyridynyl group containing nitrogen at various positions in the benzene ring. n is one of the integers 1 or 2.

### Claim 2

The compound of claim (1) where R1 and R2 are C1-3alkyl groups, and R3=phenyl, and the optional substituents in R4 and R5 are hydrogen, fluorine, chlorine or bromine.

### Claim 3

The compound of claim (1) where R1 and R2 are C1-3alkoxy groups and R3=phenyl, and the optional substituents in R4 and R5 are hydrogen, fluorine, chlorine or bromine.

### Claim 4

The compound of claim (1) where R1 and R2 are fluorine, chlorine or bromine groups and R3=phenyl, and the optional substituents in R4 and R5 are hydrogen, fluorine, chlorine or bromine.

### Claim 5

The compound of claim (1) where R1 and R2 are hydrogen and R3=phenyl, and the optional substituents in R4 are hydrogen or methyl or chlorine and R5 are hydrogen or methyl or fluorine or chlorine or methyl group or methoxy group or nitrile group.

### Claim 6

The compound of claim (1) where R1 and R2 are hydrogen, fluorine, chlorine or bromine and R3 unsubstituted pyridynyl, the pyridynyl moiety contains nitrogen at 3-position in benzene ring.

### Claim 7

A pharmaceutical composition having histamine H1-antagonists activity comprising a histamine blocking effective amount of a compound according to claim (1) and a pharmaceutically acceptable carrier.
